GSK1292263

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Diabetes Mellitus, Type 2

Phase 1

A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects

CompletedNCT01101568

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2010-04-14End: 2010-06-24Updated: 2017-06-14

Phase 2

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

CompletedNCT01119846

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2009-06-05End: 2010-03-19Updated: 2018-01-17

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

CompletedNCT01128621

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2009-11-23End: 2010-04-12Updated: 2017-10-16

Related Papers

Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies

PLoS ONE2014-04-0363 citations